BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32557833)

  • 1. Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019.
    Schjesvold F
    Eur J Haematol; 2020 Oct; 105(4):434-448. PubMed ID: 32557833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
    Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
    Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria.
    Korubo KI; Madu AJ; Okoye HC; Nwogoh B
    J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
    Merz M; Kellermann L; Poenisch W; Tischler HJ; Kohnke J; Knauf W; Goldschmidt H
    Ann Hematol; 2017 Jun; 96(6):987-993. PubMed ID: 28409228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
    Mohty M; Terpos E; Mateos MV; Cavo M; Lejniece S; Beksac M; Bekadja MA; Legiec W; Dimopoulos M; Stankovic S; Durán MS; De Stefano V; Corso A; Kochkareva Y; Laane E; Berthou C; Salwender H; Masliak Z; Pečeliūnas V; Willenbacher W; Silva J; Louw V; Nemet D; Borbényi Z; Abadi U; Pedersen RS; Černelč P; Potamianou A; Couturier C; Feys C; Thoret-Bauchet F; Boccadoro M;
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e401-e419. PubMed ID: 30030033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma: practice patterns across Europe.
    Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
    Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
    Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
    Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
    Takeda Y; Sakaida E; Nakaseko C
    Nihon Rinsho; 2015 Jan; 73(1):130-6. PubMed ID: 25626318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and management guideline for multiple myeloma].
    Murakami H; Handa H; Saitoh T
    Nihon Rinsho; 2007 Dec; 65(12):2167-76. PubMed ID: 18069257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
    Terpos E; Ntanasis-Stathopoulos I;
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma in the Time of COVID-19.
    Al Saleh AS; Sher T; Gertz MA
    Acta Haematol; 2020; 143(5):410-416. PubMed ID: 32305989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study.
    Kerbauy LN; Parmar S; Kutner JM; Gusmão BM; Hamerschlak N
    Sao Paulo Med J; 2016; 134(4):335-41. PubMed ID: 27557143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma.
    Dimopoulos MA; Terpos E
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii143-50. PubMed ID: 20943607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
    Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
    Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
    Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.